Date:8/23/2007

ed results as a result of a number of factors, including the fact that preliminary results involved only a small number of test mice, the subsequent investigations were limited in scope, the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs, (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials) the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in the Company's periodic report on Form 10-QSB for the three months ended June 30, 2007 and on Form 10-KSB for the twelve months ended December 31, 2006 as filed with the Securities and Exchange Commission. There are no guarantees that any of the Company's proposed products will prove to be commercially successful. The Company undertakes no duty to update forward-looking statements.

MEDIA CONTACT:

W. Jason Grimley

Spelling Communications

310-477-9500

jgrimley@spellcom.com

'/>"/>

SOURCE ImmuneRegen BioSciences, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Third Wave responds to Digene patent lawsuit
2. Epic responds to critics of electronic record installation
3. Small Tree Communications awarded $2.85M defense contract
4. Research consortium aims to bring security and defense contracts to Wisconsin
5. MATC student team wins cyber defense contest
6. National Bio and Agro Defense fits Wisconsin
7. Chippewa Valley firms land more defense work
8. Wisconsins failure to attract federal defense dollars crimps tech economy
9. Defense contract helps Plexus gain record profits
10. Chippewa Valley to get $46 million in defense spending
11. Wisconsins untapped defense might: why saving military bases is just a start